产品
编 号：F281612
分子式：C28H33N7O2S
分子量：531.67
分子式：C28H33N7O2S
分子量：531.67
产品类型
规格
价格
是否有货
结构图
CAS No: 2245072-20-0
产品详情
生物活性：
LIT-001 free base is the first nonpeptide oxytocin receptor (OT-R) agonist (EC50=55 nM; Ki=226 nM). LIT-001 free base improves social interaction in a mouse model of autism.
体内研究：
LIT-001 free base (10-20 mg/kg; i.p.) alleviates core symptoms in the context of autism spectrum disorders (ASD ).Animal Model:Oprm1–/– mice (bred in house on a 50% 129SVPas–50% C57BL/6J hybrid background)
Dosage:10, 20 mg/kg
Administration:i.p.
Result:Alleviated core symptoms in the context of ASD.
体外研究：
In vitro signaling experiments, LIT-001 free base is a nonbiased OT-R agonist on the two main signaling pathways of this receptor, with minor antagonist effect on V1a and agonist effect on V1b receptors, observed at high concentrations only.
LIT-001 free base is the first nonpeptide oxytocin receptor (OT-R) agonist (EC50=55 nM; Ki=226 nM). LIT-001 free base improves social interaction in a mouse model of autism.
体内研究：
LIT-001 free base (10-20 mg/kg; i.p.) alleviates core symptoms in the context of autism spectrum disorders (ASD ).Animal Model:Oprm1–/– mice (bred in house on a 50% 129SVPas–50% C57BL/6J hybrid background)
Dosage:10, 20 mg/kg
Administration:i.p.
Result:Alleviated core symptoms in the context of ASD.
体外研究：
In vitro signaling experiments, LIT-001 free base is a nonbiased OT-R agonist on the two main signaling pathways of this receptor, with minor antagonist effect on V1a and agonist effect on V1b receptors, observed at high concentrations only.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备